Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Research & Development (2016 - 2026)

Gyre Therapeutics has reported Research & Development over the past 16 years, most recently at $4.8 million for Q4 2025.

  • Quarterly Research & Development rose 29.71% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Dec 2025, up 13.92% year-over-year, with the annual reading at $13.7 million for FY2025, 13.92% up from the prior year.
  • Research & Development was $4.8 million for Q4 2025 at Gyre Therapeutics, up from $2.4 million in the prior quarter.
  • Over five years, Research & Development peaked at $20.4 million in Q3 2021 and troughed at -$50.2 million in Q4 2021.
  • The 5-year median for Research & Development is $3.4 million (2024), against an average of $2.9 million.
  • Year-over-year, Research & Development tumbled 96.05% in 2022 and then surged 274.72% in 2023.
  • A 5-year view of Research & Development shows it stood at -$50.2 million in 2021, then skyrocketed by 108.59% to $4.3 million in 2022, then increased by 6.01% to $4.6 million in 2023, then dropped by 18.74% to $3.7 million in 2024, then rose by 29.71% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Research & Development are $4.8 million (Q4 2025), $2.4 million (Q3 2025), and $3.4 million (Q2 2025).